Company intelligence / Profile preview

Canndoc

Ownership: Private
Development stage: Other

Overview

Canndoc has treated over 40,000 patients with millions of doses administered. The company has initiated multiple clinical trials including a Phase 3 trial for autism spectrum disorder in children, and trials for adult epilepsy, fibromyalgia, neuropathic pain, chemotherapy side effects, Parkinson's disease, rheumatoid arthritis, radicular pain, PTSD, and lumbar radiculopathy. Clinical evidence from over 12 years of experience treating patients, primarily in oncology, has shown reduction in patient opioid consumption.

Therapeutic areas: ImmunologyRheumatologyGastroenterologyNeurologyPsychiatryOncology
Modalities: Medical cannabis
Industry: Biotech

Drug pipeline

3 assets

Oil T5/C10

2 more assets in the full pipeline.

Partnerships

Teva Pharmaceutical Industries (through SLE distribution)TilrayAphriaCookiesCharlotte's WebOrganigramTYSON 2.0Super-PharmCellect Biotechnology

Beyond the preview

Go deeper on Canndoc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canndoc.